Literature DB >> 10913336

Orexins suppress catecholamine synthesis and secretion in cultured PC12 cells.

T Nanmoku1, K Isobe, T Sakurai, A Yamanaka, K Takekoshi, Y Kawakami, K Ishii, K Goto, T Nakai.   

Abstract

New orexigenic peptides called orexin-A and -B have recently been described in neurons of the lateral hypothalamus and perifornical area. No orexins have been found in adipose tissues or visceral organs, including the adrenal gland. However, expression of the orexin-receptor 2 (OX2R) in the rat adrenal gland has been reported. To test the effects of orexins on peripheral organs, we investigated their effects on catecholamine synthesis and secretion in the rat pheochromocytoma cell line PC12. Orexin-A and -B (100 nM) significantly reduced basal and PACAP-induced tyrosine hydroxylase (TH) (the rate-limiting enzyme in the biosynthesis of catecholamines) mRNA levels. Orexin-A and -B (100 nM) also significantly inhibited the PACAP-induced increase in the cAMP level, suggesting that the suppressive effect on TH mRNA is mediated, at least in part, by the cAMP/protein kinase A pathway. Furthermore, orexin-A and -B (100 nM) significantly suppressed basal and PACAP-induced dopamine secretion from PC12 cells. Next, we examined whether orexin receptors (OX1R, OX2R) were present in the rat adrenal gland and PC12 cells. In the adrenal glands, OX2R was as strongly expressed as in the hypothalamus, but OX1R was not detected. On the other hand, neither OX1R nor OX2R was expressed in PC12 cells. However, binding assays showed equal binding of orexin-A and -B to PC12 cells, suggesting the existence in these cells of some receptors for orexins. These results indicate that orexins suppress catecholamine release and synthesis, and that the inhibitory effect is mediated by the cAMP/protein kinase A pathway. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913336     DOI: 10.1006/bbrc.2000.3137

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  SB-334867-A: the first selective orexin-1 receptor antagonist.

Authors:  D Smart; C Sabido-David; S J Brough; F Jewitt; A Johns; R A Porter; J C Jerman
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 2.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 3.  Role of Orexin-A in Hypertension and Obesity.

Authors:  Roberta Imperatore; Letizia Palomba; Luigia Cristino
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

4.  OX2R activation induces PKC-mediated ERK and CREB phosphorylation.

Authors:  Yang Guo; Pingfu Feng
Journal:  Exp Cell Res       Date:  2012-05-29       Impact factor: 3.905

5.  Pituitary adenylate cyclase activating polypeptide modulates catecholamine storage and exocytosis in PC12 cells.

Authors:  Yan Dong; Gang Ning; Andrew G Ewing; Michael L Heien
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

6.  Global analysis of gene expression mediated by OX1 orexin receptor signaling in a hypothalamic cell line.

Authors:  Eric Koesema; Thomas Kodadek
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

Review 7.  A review of orexin's unprecedented potential as a novel, highly-specific treatment for various localized and metastatic cancers.

Authors:  Nicole L Graybill; Volkmar Weissig
Journal:  SAGE Open Med       Date:  2017-11-03

Review 8.  The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role.

Authors:  Alain Couvineau; Stéphanie Dayot; Pascal Nicole; Valérie Gratio; Vinciane Rebours; Anne Couvelard; Thierry Voisin
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-27       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.